These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7789484)

  • 1. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia.
    Rizzato G; Montemurro L; Fraioli P; Montanari G; Fanti D; Pozzoli R; Magliano E
    Eur Respir J; 1995 Mar; 8(3):398-402. PubMed ID: 7789484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections.
    Soepandi P; Mangunnegoro H; Yunus F; Gunawan J
    Respirology; 1998 Jun; 3(2):113-7. PubMed ID: 9692520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
    Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
    Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group.
    O'Doherty B; Muller O
    Eur J Clin Microbiol Infect Dis; 1998 Dec; 17(12):828-33. PubMed ID: 10052544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia.
    Bohte R; van't Wout JW; Lobatto S; Blussé van Oud Alblas A; Boekhout M; Nauta EH; Hermans J; van den Broek PJ
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):182-7. PubMed ID: 7614957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
    Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
    J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
    Griffin AT; Peyrani P; Wiemken T; Arnold F
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
    Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etiology and treatment of community-acquired pneumonia in ambulatory children.
    Wubbel L; Muniz L; Ahmed A; Trujillo M; Carubelli C; McCoig C; Abramo T; Leinonen M; McCracken GH
    Pediatr Infect Dis J; 1999 Feb; 18(2):98-104. PubMed ID: 10048679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults.
    Drehobl MA; De Salvo MC; Lewis DE; Breen JD
    Chest; 2005 Oct; 128(4):2230-7. PubMed ID: 16236879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults.
    Sopena N; Martínez-Vázquez C; Rodríguez-Suárez JR; Segura F; Valencia A; Sabrià M
    J Chemother; 2004 Feb; 16(1):102-3. PubMed ID: 15078008
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime.
    Rovira E; Martínez-Moragón E; Belda A; Gonzalvo F; Ripollés F; Pascual JM
    Respiration; 1999; 66(5):413-8. PubMed ID: 10516537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.
    Harris JA; Kolokathis A; Campbell M; Cassell GH; Hammerschlag MR
    Pediatr Infect Dis J; 1998 Oct; 17(10):865-71. PubMed ID: 9802626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia.
    Moola S; Hagberg L; Churchyard GA; Dylewski JS; Sedani S; Staley H
    Chest; 1999 Oct; 116(4):974-83. PubMed ID: 10531162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report.
    Uzun O; Hayran M; Akova M; Gür D; Akalin HE
    J Chemother; 1994 Feb; 6(1):53-7. PubMed ID: 8071680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
    Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia.
    Myburgh J; Nagel GJ; Petschel E
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():163-9. PubMed ID: 8396088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.